Drug
Docetaxel-Carboplatin
Docetaxel-Carboplatin is a pharmaceutical drug with 4 clinical trials. Currently 2 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
2(50%)
Results Posted
100%(2 trials)
Phase Distribution
Ph phase_1
1
25%
Ph phase_4
1
25%
Ph phase_2
1
25%
Ph phase_3
1
25%
Phase Distribution
1
Early Stage
1
Mid Stage
2
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Phase 4Post-market surveillance
1(25.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
2
trials recruiting
Total Trials
4
all time
Status Distribution
Active(2)
Completed(2)
Detailed Status
Recruiting2
Completed2
Development Timeline
Analytics
Development Status
Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
Phase 41 (25.0%)
Trials by Status
recruiting250%
completed250%
Recent Activity
2 active trials
Showing 4 of 4
recruitingphase_1
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
NCT02889666
recruitingphase_3
Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT03919552
completedphase_2
Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
NCT00621049
completedphase_4
Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer
NCT00883675
Clinical Trials (4)
Showing 4 of 4 trials
NCT02889666Phase 1
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
NCT03919552Phase 3
Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT00621049Phase 2
Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC
NCT00883675Phase 4
Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4